Financial
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
BD (Becton, Dickinson and Company)
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: BDX
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
Source: official results release · Year ended 2026-09-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | US$19.5bn | +4.9% | US$2.3bn | US$1.1bn | Becton, Dickinson and Company |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Feb 2026: BD completed the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, so BD diagnostics products now sit with Waters; buyers should check which entity supplies them.
Cyber & information governance
Dec 2024: CISA published an advisory on default credentials (CVE-2024-10476, CVSS 8.0) in several BD microbiology and lab systems including BACTEC, MAX and Phoenix M50; BD said it was deploying fixes through field service and no exploitation was reported. NHS DSPT status not yet checked.
Regulatory & clinical safety
Oct 2026: The FDA highlighted BD's updated recall of certain Alaris pump infusion sets that perform worse than previously disclosed at low rates, risking under- or over-infusion; BD reported no serious injuries or deaths as of Aug 2026.
Contract performance
Jun 2025: BD announced a UK partnership with Better Meds on medication management. No contract terminations or disputes involving BD found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.